PROF vs. DCTH, OBIO, DRTS, RCEL, QIPT, CVRX, CLPT, ARAY, NPCE, and UTMD
Should you be buying Profound Medical stock or one of its competitors? The main competitors of Profound Medical include Delcath Systems (DCTH), Orchestra BioMed (OBIO), Alpha Tau Medical (DRTS), AVITA Medical (RCEL), Quipt Home Medical (QIPT), CVRx (CVRX), ClearPoint Neuro (CLPT), Accuray (ARAY), NeuroPace (NPCE), and Utah Medical Products (UTMD). These companies are all part of the "surgical & medical instruments" industry.
Profound Medical (NASDAQ:PROF) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.
Profound Medical has a net margin of -386.63% compared to Delcath Systems' net margin of -1,080.72%. Profound Medical's return on equity of -70.08% beat Delcath Systems' return on equity.
Profound Medical currently has a consensus price target of $14.58, indicating a potential upside of 75.91%. Delcath Systems has a consensus price target of $20.20, indicating a potential upside of 150.62%. Given Delcath Systems' higher possible upside, analysts plainly believe Delcath Systems is more favorable than Profound Medical.
47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by company insiders. Comparatively, 17.9% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profound Medical has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.
Profound Medical has higher revenue and earnings than Delcath Systems. Profound Medical is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Profound Medical received 14 more outperform votes than Delcath Systems when rated by MarketBeat users. Likewise, 71.15% of users gave Profound Medical an outperform vote while only 22.33% of users gave Delcath Systems an outperform vote.
In the previous week, Delcath Systems had 13 more articles in the media than Profound Medical. MarketBeat recorded 21 mentions for Delcath Systems and 8 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.68 beat Delcath Systems' score of 0.56 indicating that Profound Medical is being referred to more favorably in the media.
Summary
Profound Medical beats Delcath Systems on 11 of the 18 factors compared between the two stocks.
Get Profound Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PROF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Profound Medical Competitors List
Related Companies and Tools
